Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions

Experimental Hematology

Volumn 38, Issue 11, 2010, Pages 1066-1073

  Wang, Xinchao ^a,b,c   Schmitt, Anita ^a   Chen, Baoan ^b   Xu, Xun ^a,d   Mani, Jiju ^a   Linnebacher, Michael ^a   Freund, Mathias ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; HLA A2 ANTIGEN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAGNETIC SEPARATION; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WT1 GENE;

ACUTE DISEASE; ADOPTIVE TRANSFER; ANTIGENS, CD28; ANTIGENS, CD45; BLOOD DONORS; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MAGNETICS; RECEPTORS, CCR7; WT1 PROTEINS;

EID: 78650245718     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.07.002     Document Type: Article

References (29)

1. Haber D.A., Buckler A.J., Glaser T., et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990, 60:1257-1269.
2. Miwa H., Beran M., Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992, 6:405-409.
3. Ariyaratana S., Loeb D.M. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007, 14:1-17.
4. Scheibenbogen C., Letsch A., Thiel E., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100:2132-2137.
5. Smits E.L., Berneman Z.N., Van Tendeloo V.F. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009, 14:240-252.
6. Keilholz U., Letsch A., Busse A., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
7. Yao J., Bechter C., Wiesneth M., et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 2008, 46:e96-e105.
8. Neudorfer J., Schmidt B., Huster K.M., et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007, 320:119-131.
9. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
10. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100:397-405.
11. Raiola A.M., Van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003, 31:687-693.
12. Weisser M., Tischer J., Schnittger S., Schoch C., Ledderose G., Kolb H.J. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006, 91:663-666.
13. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
14. Slavin S., Ackerstein A., Morecki S., Gelfand Y., Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant 2001, 28:795-798.
15. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
16. Morecki S., Lindhofer H., Yacovlev E., Gelfand Y., Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2006, 107:1564-1569.
17. Call K.M., Glaser T., Ito C.Y., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
18. Mundlos S., Pelletier J., Darveau A., Bachmann M., Winterpacht A., Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993, 119:1329-1341.
19. Inoue K., Sugiyama H., Ogawa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-3079.
20. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009, 27:5195-5201.
21. Oji Y., Ogawa H., Tamaki H., et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999, 90:194-204.
22. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51:99-107.
23. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95:286-293.
24. Weber G., Karbach J., Kuçi S., et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 2009, 23:1634-1642.
25. Voss S., Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng 1997, 10:975-982.
26. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110:1924-1932.
27. Morita Y., Heike Y., Kawakami M., et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer 2006, 119:1360-1367.
28. Pittet M., Rubio-Godoy V., Bioley G., et al. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003, 171:1844-1849.
29. Sallusto F., Lenig D., Förster R., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.